Human Epidermal Growth Factor Receptor 2 (HER2) is highly expressed in a significant proportion of breast, ovarian, and gastric cancers and is under-expressed in normal cells, so targeted drug delivery for cancer can be carried out by coupling ligands targeting HER2 [64]. This evidence concerns the gene ERBB2 and gastric cancer.